The drug giant convened the ten-member panel, headed by EugeneBraunwald of Harvard Medical School in Boston, to examine the safety of heart-failure treatment Natrecor.
EugeneBraunwald, a prominent Harvard cardiologist who is running a Vytorin trial, called Peto "the best statistician in the universe" while telling reporters that any cancer risk with the drug is unlikely.